Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care

Abstract

Get full access to this article

View all access options for this article.

References

Ficha técnica de vandetanib (Caprelsa®) [in Spanish]. Agencia Española de Medicamentos y Productos Sanitarios. 2022. Accessed April 20, 2026. https://cima.aemps.es/cima/dochtml/ft/11749002/FT_11749002.html

Bifimed: Buscador de la Información sobre la Situación de Financiación de los Medicamentos-Nomenclator Abril-2026 [in Spanish]. Accessed April 20, 2026. https://www.sanidad.gob.es/profesionales/medicamentos.do?metodo=verDetalle&cn=688237

Rosen

Damse

Sherman

Lacouture

Risk of rash in cáncer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125-1133. doi:10.1210/jc.2011-2677

Wang

Vasilyev

DFT structural and UV-VIS spectral insights into photosensitivity of vandetanib: a dual EGFR/SARS-CoV-2 Mpro inhibitor. Pharmaceuticals. 2025;18(9):1297. doi:10.3390/ph18091297

Salvador

Vedaldi

Brun

Dall’Acqua

Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544. Toxicol in Vitro. 2014;28(5):803-811. doi:10.1016/j.tiv.2014.03.007

Vandetanib (Caprelsa®) Prescribing Information . Food and Drug Administration (FDA). 2025. Accessed April 20, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022405s023lbl.pdf#page=21

Durr

Schlichtig

Kelz

, et al. The randomized AMBORA trial: impact of pharmacological/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents. J Clin Oncol. 2021;39(18):1983-1994. doi:10.1200/JCO.20.03088

Yin

Qiu

Zhang

A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: a case report. Medicine (Baltimore). 2019;98(31):e16392. doi:10.1097/MD.0000000000016392